Literature DB >> 21621983

Span 80 vesicles have a more fluid, flexible and "wet" surface than phospholipid liposomes.

Keita Hayashi1, Toshinori Shimanouchi, Keiichi Kato, Tatsuhiko Miyazaki, Atsushi Nakamura, Hiroshi Umakoshi.   

Abstract

The surface properties of Span 80 vesicles at various cholesterol contents, together with those of various liposomes, were characterized by using fluorescence probes. The membrane fluidity of the Span 80 vesicles was measured by 1,6-diphenyl-1.3.5-hexatriene (DPH) and trimethlyammonium-DPH (TMA-DPH), and the results suggested that the surface of the Span 80 vesicles was fluid due to the lateral diffusion of Span 80 molecules. The depolarization measured by TMA-DPH and the headgroup mobility measured by dielectric dispersion analysis indicated the high mobility of the head group of Span 80 vesicles. This suggested that the surface of Span 80 vesicles was flexible due to the head group structure of Span 80, sorbitol. In addition, spectrophotometric analysis with 6-dodecanoyl-N, N-dimethyl-2-naphthylamine and 8-anilino-1-naphthalenesulfonic acid indicated that the water molecules could easily invade into the interior of the Span 80 vesicle membrane, suggesting that the membrane surface was more wet than the liposome surface. These surface properties indicated that the protein could interact with the interior of vesicle membranes, which was similar to the case of cholesterol. Thus the present results confirmed that the Span 80 vesicle surfaces showed the unique characteristics of fluidity, flexibility, and "wetness", whereas the liposome surfaces did not.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21621983     DOI: 10.1016/j.colsurfb.2011.04.029

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  8 in total

1.  Simultaneous Optimization of Oral and Transdermal Nanovesicles for Bioavailability Enhancement of Ivabradine Hydrochloride.

Authors:  Marianne Joseph Naguib; Ibrahim Elsayed; Mahmoud Hassan Teaima
Journal:  Int J Nanomedicine       Date:  2021-04-21

2.  Enhanced cytotoxicity for colon 26 cells using doxorubicin-loaded sorbitan monooleate (Span 80) vesicles.

Authors:  Keita Hayashi; Tsuyoshi Tatsui; Toshinori Shimanouchi; Hiroshi Umakoshi
Journal:  Int J Biol Sci       Date:  2013-01-17       Impact factor: 6.580

3.  Development of tumor-specific caffeine-potentiated chemotherapy using a novel drug delivery system with Span 80 nano-vesicles.

Authors:  Hiroshi Nakata; Tatsuhiko Miyazaki; Tomoyuki Iwasaki; Atsushi Nakamura; Teruki Kidani; Kenshi Sakayama; Junya Masumoto; Hiromasa Miura
Journal:  Oncol Rep       Date:  2015-01-29       Impact factor: 3.906

4.  Liposomes modified with cardiolipin can act as a platform to regulate the potential flux of NADP+-dependent isocitrate dehydrogenase.

Authors:  Keishi Suga; Akari Hamasaki; Junpei Chinzaka; Hiroshi Umakoshi
Journal:  Metab Eng Commun       Date:  2015-11-12

5.  Controlled rate slow freezing with lyoprotective agent to retain the integrity of lipid nanovesicles during lyophilization.

Authors:  Eunhye Yang; Hyunjong Yu; SungHak Choi; Kyung-Min Park; Ho-Sup Jung; Pahn-Shick Chang
Journal:  Sci Rep       Date:  2021-12-21       Impact factor: 4.379

6.  Active Targeting to Osteosarcoma Cells and Apoptotic Cell Death Induction by the Novel Lectin Eucheuma serra Agglutinin Isolated from a Marine Red Alga.

Authors:  Keita Hayashi; Peter Walde; Tatsuhiko Miyazaki; Kenshi Sakayama; Atsushi Nakamura; Kenji Kameda; Seizo Masuda; Hiroshi Umakoshi; Keiichi Kato
Journal:  J Drug Deliv       Date:  2012-12-27

7.  Investigation of Fatty Acid Ketohydrazone Modified Liposome's Properties as a Drug Carrier.

Authors:  Keita Hayashi; Madoka Kiriishi; Keishi Suga; Yukihiro Okamoto; Hiroshi Umakoshi
Journal:  J Drug Deliv       Date:  2015-11-16

8.  Niosomes, an alternative for liposomal delivery.

Authors:  Rianne Bartelds; Mohammad Hadi Nematollahi; Tjeerd Pols; Marc C A Stuart; Abbas Pardakhty; Gholamreza Asadikaram; Bert Poolman
Journal:  PLoS One       Date:  2018-04-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.